On January 5, 2023 Caris Life Sciences(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, and Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, reported an expansion of their collaboration to research, develop and commercialize novel XmAb bispecific and multi-specific antibodies directed against novel targets, identified and proposed by Caris, for the treatment of patients with cancer (Press release, Xencor, JAN 5, 2023, View Source [SID1234625982]).

Building upon the initial August 2022 agreement, this expanded collaboration will increase the number of targets and cancer types that Caris will interrogate with its proprietary, multi-omics discovery engine platform, Caris Discovery. Novel targets and their accompanying validation packages will serve as the substrate for drug candidate development through Xencor’s XmAb platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Xencor has an impressive track record of advancing drug development programs from early discovery through to the clinic, and we are excited to bring forward additional novel targets for their team," said David Spetzler, M.S., Ph.D., MBA, President and Chief Scientific Officer of Caris Life Sciences. "The aggregate strength of Caris’ platform permits the unlocking of otherwise inaccessible targets, and we look forward to realizing our shared goal of bringing novel antibody-directed therapies to patients with cancer."

"We are committed to leveraging our XmAb bispecific antibody platforms, building an internal portfolio of novel drug candidates and advancing potentially transformational treatment options for patients," said John Desjarlais, Ph.D., Senior Vice President and Chief Scientific Officer of Xencor. "Our new agreement with Caris expands a progressing collaboration centered on their innovative target discovery and precision oncology capabilities."

Under the terms of the new agreement, Xencor will receive exclusive worldwide rights to research, develop and commercialize products directed to up to three targets discovered under the collaboration. Caris will receive an upfront payment and will be eligible to receive up to $187 million in development and commercial milestone payments. Caris will also be eligible to receive royalties on net sales of commercialized products resulting from the collaboration as well as future rights for molecular profiling and companion diagnostics.

Caris Discovery leverages the aggregate strength of Caris’ unmatched platform, combining insights generated from the molecular interrogation of primary patient tissues using ADAPT, the company’s exclusive aptamer-based proteomic profiling platform; a robust validation pipeline; and the company’s proprietary real-world data platform that integrates Caris’ extensive catalog of molecular and clinical data. Learn more about Caris Discovery here.

XmAb is a registered trademark of Xencor, Inc.